Hollandbio welcomes DELPHINIUM as a new member
Hollandbio connects, represents, and supports the Dutch life science sector. We are very proud that we already represent 260 companies: from start-ups, small and medium-sized companies to large companies, active in health, food, or the biobased economy. Today, we are happy to introduce DELPHINIUM as a new member! Based in Groningen, DELPHINIUM strengthens the Dutch biotech ecosystem with a specialized clinic focused on early-phase clinical drug development. Their 12-bed facility offers end-to-end Phase I services, including clinical operations, medical writing, biostatistics, pharmacokinetics, and data management. As a Phase I clinic, DELPHINIUM conducts first-in-human studies, typically involving healthy volunteers. These trials are critical for assessing the safety, tolerability, and pharmacokinetics of new drug candidates before they move into later-stage trials with patients. With an experienced team and a dedicated facility, DELPHINIUM ensures that early-phase research is conducted safely, efficiently, and in full compliance with regulatory standards.
Furthermore, DELPHINIUM also supports companies within the Dutch biotech ecosystem with the variety in challenges they may encounter during their research, such as volunteer recruitment, regulatory affairs, or simply by offering their facilities, study staff and experience.
DELPHINIUM was founded with a clear mission: to empower small biotech companies through the most challenging early stages of development. By providing tailored solutions, DELPHINIUM ensures efficient and flexible approaches to early-phase clinical programs. They collaborate with preferably local vendors who understand the challenges faced by smaller biotechs and share their commitment to supporting them through this critical phase.
By joining Hollandbio, DELPHINIUM aims to connect with like-minded biotech innovators, raise awareness of their unique offering, and contribute to a thriving early-phase landscape in the Netherlands. Many companies remain unaware of the excellent, well-established clinic located on the UMCG grounds — something DELPHINIUM is determined to change.
Led by CEO Jitske Beukema, COO/CMO, Christine Voors-Pette MD, and CFO Agnes Boelens-van Nieff, DELPHINIUM brings decades of experience in clinical research. Their commitment to quality, flexibility, and personalized service makes them a valuable addition to the Dutch biotech landscape.
If you’re looking for a partner who truly understands the biotech mindset – practical, competitive, and committed – DELPHINIUM is ready to help you move forward.
Learn more at www.delphiniumcro.com
